TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.6 MULTIVARIATE MODELLING 43
2.7 MARKET APPLICATION COVERAGE GRID 44
2.8 PRODUCT LIFELINE CURVE 45
2.9 DBMR MARKET POSITION GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PESTEL ANALYSIS 52
4.2 PORTER FIVE FORCES 53
4.3 PATENT ANALYSIS 54
4.4 PATIENT FLOW DIAGRAM 55
4.5 KEY PRICING STRATEGIES 56
4.6 FUTURE THERAPIES 57
4.7 KEY PATIENT ENROLLMENT STRATEGIES 58
5 PIPELINE ANALYSIS 59
6 EPIDEMIOLOGY 60
7 INDUSTRY INSIGHTS 61
8 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: REGULATIONS 62
9 MARKET OVERVIEW 65
9.1 DRIVERS 67
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
9.1.3 AWARENESS REGARDING THE DISEASE 68
9.2 RESTRAINTS 68
9.2.1 STRICT REGULATORY GUIDELINES 68
9.2.2 HIGH TREATMENT COSTS 68
9.3 OPPORTUNITIES 69
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
9.3.2 INCREASING HEALTHCARE FACILITIES 69
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
9.4 CHALLENGES 70
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71
10 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72
10.1 OVERVIEW 73
10.2 TREATMENT 76
10.2.1 MEDICATIONS, BY TYPE 76
10.2.1.1 CORTICOSTEROIDS 77
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
10.2.1.2.1 AZATHIOPRINE 78
10.2.1.2.2 MYCOPHENALATE MOFETIL 78
10.2.1.2.3 METHOTREXATE 78
10.2.1.2.4 CYCLOPHOSPHAMIDE 78
10.2.1.2.5 MIZORIBINE 78
10.2.1.2.6 OTHERS 78
10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
10.2.1.3.2 TETRACYCLINE 79
10.2.1.3.3 OTHERS 79
10.2.1.4 BIOLOGICS 79
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
10.2.1.6 ANTIBIOTICS 79
10.2.1.7 ANTIFUNGALS 79
10.2.1.8 ANTIVIRALS 79
10.2.1.9 OTHER MEDICATIONS 79
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
10.2.2.1 ORAL 80
10.2.2.2 TOPICAL 80
10.2.2.3 PARENTERAL 80
10.2.2.4 OTHERS 80
10.2.3 MEDICATIONS, BY DRUG TYPE 80
10.2.3.1 GENERIC 81
10.2.3.2 BRANDED 81
10.3 DIAGNOSIS 81
10.3.1 SKIN BIOPSY 82
10.3.2 BLOOD TEST 82
10.3.3 ENDOSCOPY 82
11 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83
11.1 OVERVIEW 84
11.2 ADULTS 87
11.3 GERIATRIC 88
11.4 PEDIATRIC 89
12 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER 90
12.1 OVERVIEW 91
12.2 HOSPITALS 94
12.3 SPECIALTY CLINICS 94
12.4 RESEARCH INSTITUTES 95
12.5 OTHERS 96
13 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97
13.1 OVERVIEW 98
13.2 HOSPITALS PHARMACY 101
13.3 RETAIL PHARMACY 101
13.4 ONLINE PHARMACY 102
14 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY REGION 103
14.1 NORTH AMERICA 104
14.1.1 U.S. 112
14.1.2 CANADA 116
14.1.3 MEXICO 120
15 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 124
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 124
16 SWOT ANALYSIS 125
17 COMPANY PROFILE 126
17.1 ABBVIE INC. 126
17.1.1 COMPANY SNAPSHOT 126
17.1.2 REVENUE ANALYSIS 126
17.1.3 COMPANY SHARE ANALYSIS 127
17.1.4 PRODUCT PORTFOLIO 127
17.1.5 RECENT DEVELOPMENTS 128
17.2 MERCK & CO., INC., 129
17.2.1 COMPANY SNAPSHOT 129
17.2.2 REVENUE ANALYSIS 129
17.2.3 COMPANY SHARE ANALYSIS 130
17.2.4 PRODUCT PORTFOLIO 130
17.2.5 RECENT DEVELOPMENT 130
17.3 SANOFI 131
17.3.1 COMPANY SNAPSHOT 131
17.3.2 REVENUE ANALYSIS 131
17.3.3 COMPANY SHARE ANALYSIS 132
17.3.4 PRODUCT PORTFOLIO 132
17.3.5 RECENT DEVELOPMENT 132
17.4 REGENERON PHARMACEUTICALS INC. 133
17.4.1 COMPANY SNAPSHOT 133
17.4.2 REVENUE ANALYSIS 133
17.4.3 COMPANY SHARE ANALYSIS 134
17.4.4 PRODUCT PORTFOLIO 134
17.4.5 RECENT DEVELOPMENT 134
17.5 NOVARTIS AG 135
17.5.1 COMPANY SNAPSHOT 135
17.5.2 REVENUE ANALYSIS 135
17.5.3 COMPANY SHARE ANALYSIS 136
17.5.4 PRODUCT PORTFOLIO 136
17.5.5 RECENT DEVELOPMENT 136
17.6 AMGEN INC. 137
17.6.1 COMPANY SNAPSHOT 137
17.6.2 REVENUE ANALYSIS 137
17.6.3 PRODUCT PORTFOLIO 138
17.6.4 RECENT DEVELOPMENTS 138
17.7 ASTRAZENECA 139
17.7.1 COMPANY SNAPSHOT 139
17.7.2 REVENUE ANALYSIS 139
17.7.3 COMPANY SHARE ANALYSIS 140
17.7.4 PRODUCT PORTFOLIO 140
17.7.5 RECENT DEVELOPMENTS 141
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 142
17.8.1 COMPANY SNAPSHOT 142
17.8.2 REVENUE ANALYSIS 142
17.8.3 PRODUCT PORTFOLIO 143
17.8.4 RECENT DEVELOPMENT 143
17.9 CELLTRION HEALTHCARE CO., LTD 144
17.9.1 COMPANY SNAPSHOT 144
17.9.2 REVENUE ANALYSIS 144
17.9.3 PRODUCT PORTFOLIO 145
17.9.4 RECENT DEVELOPMENTS 145
17.10 F. HOFFMANN- LA ROCHE LTD. 146
17.10.1 COMPANY SNAPSHOT 146
17.10.2 REVENUE ANALYSIS 146
17.10.3 PRODUCT PORTFOLIO 147
17.10.4 RECENT DEVELOPMENT 147
17.11 FRESENIUS KABI AG 148
17.11.1 COMPANY SNAPSHOT 148
17.11.2 REVENUE ANALYSIS 148
17.11.3 PRODUCT PORTFOLIO 149
17.11.4 RECENT DEVELOPMENT 149
17.12 GSK PLC 150
17.12.1 COMPANY SNAPSHOT 150
17.12.2 REVENUE ANALYSIS 150
17.12.3 PRODUCT PORTFOLIO 151
17.12.4 RECENT DEVELOPMENT 151
17.13 JOHNSON & JOHNSON SERVICES, INC. 152
17.13.1 COMPANY SNAPSHOT 152
17.13.2 REVENUE ANALYSIS 152
17.13.3 COMPANY SHARE ANALYSIS 153
17.13.4 PRODUCT PORTFOLIO 153
17.13.5 RECENT DEVELOPMENT 153
17.14 LILLY 154
17.14.1 COMPANY SNAPSHOT 154
17.14.2 REVENUE ANALYSIS 154
17.14.3 PRODUCT PORTFOLIO 155
17.14.4 RECENT DEVELOPMENT 155
17.15 PFIZER INC. 156
17.15.1 COMPANY SNAPSHOT 156
17.15.2 REVENUE ANALYSIS 156
17.15.3 PRODUCT PORTFOLIO 157
17.15.4 RECENT DEVELOPMENT 157
17.16 RAKSHIT DRUGS PVT. LTD 158
17.16.1 COMPANY SNAPSHOT 158
17.16.2 PRODUCT PORTFOLIO 158
17.16.3 RECENT DEVELOPMENT 158
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 159
17.17.1 COMPANY SNAPSHOT 159
17.17.2 REVENUE ANALYSIS 159
17.17.3 PRODUCT PORTFOLIO 160
17.17.4 RECENT DEVELOPMENT 160
17.18 ZYDUS GROUP 161
17.18.1 COMPANY SNAPSHOT 161
17.18.2 REVENUE ANALYSIS 161
17.18.3 PRODUCT PORTFOLIO 162
17.18.4 RECENT DEVELOPMENT 162
18 QUESTIONNAIRE 163
19 RELATED REPORTS 165

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.